海思科(002653.SZ)：擬出售海外控股子公司暨在研項目TYK2產品 最高有望獲1.8億美元轉讓款
格隆匯 3 月 8日丨海思科(002653.SZ)公佈，公司之控股三級子公司FronThera International Group Limited( “FT集團”)擬與專注於生物技術和生命科學投資的美國風投公司Foresite Capital, LLC(“Foresite Capital”)設立的非上市公司FL2021-001, Inc.簽署《STOCK PURCHASE AGREEMENT》等交易協議，將其全資子公司FronThera U.S. Holdings Inc.(“FT控股”)之全部股權轉讓給FL2021-001,Inc.。FT集團有望獲得最高合計1.8億美元的轉讓款，其中包含首付款6000萬美元及最高1.2億美元的里程碑款。協議中約定的後續里程碑款需滿足一定的條件，故最終里程碑付款金額、付款時點尚存在不確定性。
FT控股及其全資子公司FronThera U.S. Pharmaceuticals LLC(“FT醫藥”)除仍擁有在研項目TYK2產品外，所有非TYK2產品的在研項目所屬專利和權益等將轉給海思科，涉及到Autotaxin、THR-β、Ask1、Nrf2、hemoglobin modifier等。
公司在研的TYK2產品屬於口服選擇性酪氨酸激酶2(TYK2)抑制劑。TYK2是一種介導免疫信號的非受體酪氨酸激酶,主要介導IL-23、IL-12和I型干擾素驅動的信號通路，但不介導其他激酶(如IL-6、造血生長因子和IL-2家族)驅動的細胞因子應答。TYK2信號參與多種免疫相關疾病的的病理生理過程，如銀屑病、狼瘡和炎症性腸炎等，故TYK2抑制劑針對上述疾病均有可能成藥。
目前全球尚未有TYK2抑制劑獲批上市，進展最快的同類在研化合物為BMS-986165，其開展了多項臨牀研究，涉及多種疾病。公司在研的TYK2產品立項於2018年，主要包括FTP-637等化合物。截至目前，FTP-637除在澳洲進行了部分一期臨牀試驗外，尚未開展其他臨牀試驗。
根據交易協議，FT集團可獲得首付款6000萬美元，後續里程碑付款金額、付款時點尚存在不確定性。故根據上述首付款及公司對FT集團的持股比例等，初步預計公司通過此次交易將在2021年獲得歸屬於母公司所有者的淨利潤約2.17億元(具體以期末經審計後的財務數據為準)。此次交易對公司財務狀況未來的進一步的影響需根據後續FT集團獲得的里程碑款項金額及時點預計。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
